This report describes the effects of endotoxin and a thromboxane receptor antagonist, L-655,240, on kidney function and the intrarenal pharmacokinetics of aminoglycosides. The rationale for these studies was that thromboxane antagonists may eventually be used in combination with aminoglycosides in patients with gram-negative sepsis and endotoxemia. As aminoglycosides are nephrotoxic and endotoxin has already been shown to increase the renal uptake of gentamicin, we investigated the possibility that thromboxane antagonists might interfere with the nephrotoxic potential of both substances. A decrease in the volume of distribution and an increase in the intracortical concentrations of gentamicin were observed in animals given endotoxin. Compared with animals given endotoxin alone, those which received endotoxin plus L-655,240 had significant accumulation of gentamicin in the renal cortex and medulla, as determined by the area under the concentration-time curve, and a significant reduction in the total clearance of the antibiotic (P < 0.05). This difference in uptake could not be attributed to hypotension or changes in the glomerular filtration rate or renal plasma flow. L-655,240 alone did not modify gentamicin pharmacokinetics but did decrease p-aminohippuric acid secretion. Thromboxane antagonists in the context of endotoxemia increase intrarenal uptake of aminoglycosides. If these compounds are to be used as therapeutic agents when endotoxin is present, their influence on renal handling of nephrotoxic drugs needs to be considered. Multiple-dosing regimens deserve investigation.
Aminoglycosides are potentially nephrotoxic drugs which are often given to patients with gram-negative bacteremia, in whom endotoxemia is common and may lead to endotoxin shock. Previous studies in our laboratory revealed that endotoxin may increase the intrarenal uptake of aminoglycosides and their nephrotoxic potential: greater accumulation of gentamicin (3, 6, 36) and higher toxicity (3, 36) were found in the cortexes and medullas of endotoxin-treated rats than in those of animals that received only gentamicin. It is known that endotoxin activates the metabolites of arachidonic acid, e.g., leukotrienes, prostaglandins, and thromboxanes. Because these vasoactive hormones play an active role in renal circulation and because thromboxane levels are usually low in normal kidneys (19) but greatly increase after endotoxin (4), we hypothesized that they might influence the kinetic or physiologic interaction of aminoglycoside antibiotics with proximal tubular kidney cells.
Therapy of the future will combine the use of antibiotics, monoclonal antibodies directed against endotoxin, and several kinds of biological response modifiers, including anticytokines and antagonists of thromboxanes. Because the influence of these vasoactive agents on the renal handling of aminoglycosides has not been established, we designed the following study to evaluate the influence of a specific thromboxane A2 (TXA2) antagonist (L-655,240) on the pharmacokinetics and renal uptake of gentamicin in an experimental model of endotoxemia.
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MATERIALS AND METHODS
Animals and treatments in distribution studies. Female Sprague-Dawley rats weighing 175 to 230 g were used for all experiments, as we already reported an influence of endotoxin on the renal handling of drugs with this model (9). Groups of at least six animals were anesthetized by intraperitoneal injection of sodium pentobarbital (45 mg/kg), followed 2 h later by a second dose of 20 mg/kg. Catheters were inserted into the right jugular vein for infusion of solutions. Escherichia coli 0127:B8 endotoxin (0.25 mg/kg; Sigma Chemical Company, St. Louis, Mo.) or normal saline was infused intravenously for 15 min at the beginning of the experiment. This small endotoxin dose was chosen to avoid major physiological disturbances that could lead to death and was established in accordance with previously published findings from our laboratory (9).
The TXA2 antagonist L-655,240 (Merck Frosst Canada Inc., Pointe-Claire, Quebec, Canada) was dissolved in sterile normal saline by adding anhydrous sodium carbonate (10 mg/kg) on the day of the experiment. L-655,240 {3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl] 2,2-dimethylpropanoic acid} is an indole analog, structurally related to the anti-inflammatory agent indomethacin, and a potent thromboxane receptor antagonist. The infusion was started with a 0.5-mg/kg intravenous injection given over a 1-min period either 10 min before endotoxin to prevent early manifestations of endotoxin or 2 h 58 min after endotoxin, just prior to antibiotic therapy, as would occur in clinical situations. The initial injection of L-655,240 was followed by a continuous infusion (0.5 mg/kg/h) until the animals were sacrificed to ensure constant levels of the antagonist. Control animals received normal saline throughout the experiment. Three hours after endotoxin administration, an intravenous bolus 
Endotoxin V Gentamicin a Endotoxin, L-655,240, and gentamicin at 0.25, 0.5, and 10 mg/kg, respectively, were given as an intravenous bolus. The initial injection of L-655,240 was followed by a continuous infusion at a rate of 0.5 mg/kg/h until sacrifice.
V, vehicle of endotoxin or L-655,240 was given as a control.
of gentamicin (10 mg/kg; Schering Canada, Pointe-Claire, Quebec, Canada) was given. Table 1 shows the different treatment regimens.
At 5 min and 1, 2, and 4 h after the injection of gentamicin, at least six animals per group were killed by cardiac puncture. Blood was centrifuged, and serum was collected. Both kidneys were removed, and the cortexes and medullas were dissected and homogenized in 0.1 M phosphate buffer (pH 7.4). Urine was also collected by suprapubic puncture from 0 to 1, 1 to 2, 2 to 3, and 3 to 4 h after gentamicin administration. The concentrations of gentamicin in serum, renal tissue, and urine were determined by a standard disk biological assay (12 Physiological studies. Blood pressure was recorded with an R711 physiograph (Beckman Instruments, Inc., Fullerton, Calif.) in all groups from 0 to 7 h after the beginning of the experiments (that is, from a few minutes before the beginning of the infusion of L-655,240 until the last sacrifice 4 h after gentamicin injection). These studies were done with rats other than those used in the previous experiments (three animals in each experimental group; Table 1 ).
Renal function was evaluated from 1 to 2.5 h following gentamicin injection to get information on renal circulation when tubular cells are actively taking up gentamicin. In these experiments, at least four additional rats in each group were anesthetized with pentobarbital (45 mg/kg). The left carotid artery and the right jugular vein were cannulated with type PE-50 and type PE-20 polyethylene tubing (Clay Adams, Parsippany, N.J.), respectively. The former was used to sample blood, while the latter was used for infusion. Immediately after gentamicin treatment, a 1-ml bolus of 0.85% NaCl containing [14CJinulin (0.10 mCi/100 ml; New England Nuclear Corp., Boston, Mass.), [p-3H]aminohippuric acid (PAH; 0.50 mCi/100 ml; New England Nuclear Corp.), unlabelled inulin (1 mg/ml), and unlabelled PAH (10 mg/ml) was infused at a rate of 0.28 ml/min. This bolus was immediately followed by a continuous infusion of the same solution at a rate of 0.052 ml/min; 1 h later, urine was collected for three sequential 30-min periods from the right ureter, which had previously been cannulated with type PE-10 tubing.
Blood samples were taken at the beginning and end of each urine collection period. At the end of the last period, blood was also taken from the renal vein to measure renal plasma flow (RPF (29) .
RESULTS
Aminoglycoside pharmacokinetics. Levels of gentamicin in serum and pharmacokinetic data measured in all groups are presented in Tables 2 and 3 . Endotoxin given 3 h prior to gentamicin (group E+G) significantly decreased the V.. of gentamicin compared with that in control animals that received gentamicin alone (group G). This correlated with early (5 min postinjection) high antibiotic levels in serum, as normal levels were found thereafter. Renal uptake of gentamicin from 30 min to 4 h was disturbed, with increased accumulation in the cortex in group E+G compared with group G (P < 0.05; Fig. 1 LG or group L+G) did not significantly modify gentamicin uptake in the renal cortex or medulla ( Fig. 1 and  2 ). Pharmacokinetic data derived from sera of animals treated by long-term continuous infusion of the antagonist (group L+G; Endotoxin plus L-655,240, either group E+LG or group LE+G resulted in striking uptake of gentamicin in both the cortex (P < 0.05 compared with group E+G or G; Fig. 1 ) and the medulla (P < 0.05 compared with group G; Fig. 2 ). Pharmacokinetic parameters derived from serum data (Tables 2 and 3) revealed high levels of gentamicin in serum at 5 and 30 min, followed by a rapid decline, a large AUC, a low volume of distribution, and reduced CL in groups E+LG and LE+G compared with group G. Levels in serum from 30 min to 4 h never exceeded 16.9 ,ug/ml, while renal levels for the same period were extremely high, especially in groups given a combination of the endotoxin plus the antagonist, with cortical levels reaching 105 ,ug/g of tissue at 2 h in the LE+G group. Urinary excretion of gentamicin over the 4-h period was 20 to 30% lower in all of the groups that received endotoxin (E+G, E+LG, and LE+G) than in animals that did not (groups G, LG, and L+G), but no statistical difference could be demonstrated among mean levels from any group.
Physiological studies. (i) Blood pressure. Gentamicin given alone (group G) or with L-655,240 (group L+G) did not alter blood pressure (Fig. 3) . Endotoxin (group E+G) resulted in a transient drop (90 to 70 mm Hg) in diastolic pressure between the first and second hours postendotoxin injection, followed by a return to normal, with a subsequent 15-mm Hg drop in mean arterial pressure from 3.5 h to the end of the experiment. An early decrease in the systolic and diastolic pressures happened with the antagonist-plus-endotoxin combination (group LE+G), but no further decrease was observed thereafter. In all of the treatments, no major fall in blood pressure occurred, as large endotoxin doses are necessary to induce lethal hypotension or major physiological disturbances in Sprague-Dawley rats.
(ii) Renal finction. TXA2 results in vascular smooth muscle contraction, can .3. Systolic and diastolic blood pressures from 0 to 7 h in increase membrane permeability in some instances (30) , and
Is that received gentamicin alone at 10 mg/kg at time 3 h (A), may decrease the GFR and RPF (17) although L-655,240 did not significantly modify gentamicin uptake when given alone to normal animals, it did contribute to an increase in the amount of the drug taken up by kidney i (three 30-min periods ranging from 1 to 2.5 h postgencells of endotoxemic animals to the same extent in both of in). L-655,240 infused over a long period, either alone the treatment regimens tested. A significant increase in drug p L+G) or in combination with the endotoxin (group levels was also noted in the medulla following administration G), significantly reduced TPAH (P < 0.05). RPF (44, 45) induces an intense inflammatory cantly from those of controls. We do not exclude, however, on through the release of cytokines, metabolites of the possibility that the GFR and RPF were modified in the idonic acid and nitric oxide (26, 28, 35, 41) which lead hours preceding gentamicin administration, that is, during lotoxin shock characterized by systemic hypotension, the first 3 h after endotoxin administration, since the GFR edema, decreased renal perfusion, and death. In the still appeared to be low in all of the endotoxin-treated groups compared with that of nonendotoxemic animals. In fact, the slight fall in blood pressure, the GFR, and the V.s of gentamicin in the endotoxemic groups, which may have resulted from altered peripheral blood distribution, may have contributed to the early increase in the levels of gentamicin in serum with ensuing better availability of the drug for proximal tubular cells, which, in endotoxin-treated rats, avidly bind gentamicin after glomerular filtration (10, 11) and rapidly incorporate the drug within their lysosomes to induce renal damage (2) .
We cannot exclude the possibility that binding between blood high-density lipoproteins, endotoxin (48) , and gentamicin (44) , could have contributed to the high levels in serum, the low sCL, and the slow urinary excretion of the antibiotic. As for the renal levels of antibiotic, they were always higher than those in the serum, suggesting that the minimal amount of blood remaining within tissue after bleeding of the animal cannot explain our findings. As we have observed previously, a direct interaction between aminoglycosides and endotoxin at the tubular cell level is also possible, as both molecules interact with phospholipids (2, 21) and can disturb membrane transport and induce lysosomal changes (27) .
The activity of L-655,240 in the kidneys has not been well characterized. It is known that TXA2 influences renal vasculature and that TXA2 receptors present in arterial and venous smooth muscles are also expressed in kidney cells (17, 38) , but the precise location of the receptors in the nephron has not been reported. Mesangial cells and glomeruli are able to synthesize TXA2 (4), and since this lipid has a short t112 (43) , there is strong possibility that receptors for TXA2 are on neighboring cells and that L-655,240 reacts with these receptors (22) . However, as these receptors are not precisely identified in the nephron, and as we do not know the influence of L-655,240 on other phospholipid receptors, it would be premature to suggest, on the basis of our results, a synergistic biochemical interaction among endotoxin, aminoglycosides, and this compound at the tubular level.
L (33) . The changes in aminoglycoside pharmacology that we have observed may thus have been the results of combined systemic and local effects of L-655,240 on tubular cells of endotoxemic animals.
In conclusion, we found that the combination of endotoxin plus L-655,240 increased the total amount of gentamicin within the kidneys. The risk of increased nephrotoxicity must, however, be investigated after multiple-dosing physiologic end-point studies, as a high accumulation rate does not always correlate with a high risk of nephrotoxicity. This was the case with previous studies in our laboratory, as polyaspartic acid and daptomycin prevented gentamicin and tobramycin nephrotoxicity despite similar or greater renal aminoglycoside accumulation (5, 6) . On the basis of our results, thromboxane antagonists may have to be used with caution in patients given aminoglycosides, a conclusion which should be evaluated in humans.
